Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Symbicort and Pulmicort on HAT/HDAC activity in sputum cells from COPD patients
2005-003297-13Phase 4Terminated
- Sponsor
- Imperial College London
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of budesonide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Imperial College London. Primary endpoint: HDAC and HAT activity ratio. Started Oct 2005; status: terminated.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-003297-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003297-13.